Lifevantage (NASDAQ:LFVN) Stock Price Crosses Above 200 Day Moving Average – What’s Next?
by Scott Moore · The Cerbat GemLifevantage Corporation (NASDAQ:LFVN – Get Free Report) crossed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $5.56 and traded as high as $5.72. Lifevantage shares last traded at $5.61, with a volume of 110,640 shares trading hands.
Analyst Upgrades and Downgrades
Several research firms have weighed in on LFVN. Loop Capital set a $5.00 price target on Lifevantage in a research report on Thursday, February 5th. Lake Street Capital downgraded shares of Lifevantage from a “buy” rating to a “hold” rating and set a $5.00 target price on the stock. in a report on Thursday, May 7th. Finally, Weiss Ratings downgraded shares of Lifevantage from a “hold (c)” rating to a “hold (c-)” rating in a research report on Monday, May 4th. Two analysts have rated the stock with a Hold rating, According to data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $5.00.
View Our Latest Stock Report on LFVN
Lifevantage Stock Performance
The company has a market capitalization of $70.80 million, a P/E ratio of 12.47 and a beta of 0.52. The stock’s 50 day moving average price is $4.80 and its 200 day moving average price is $5.56.
Lifevantage (NASDAQ:LFVN – Get Free Report) last posted its earnings results on Wednesday, May 6th. The company reported $0.12 EPS for the quarter, missing the consensus estimate of $0.16 by ($0.04). The business had revenue of $43.72 million for the quarter, compared to the consensus estimate of $47.77 million. Lifevantage had a return on equity of 23.89% and a net margin of 2.94%. On average, analysts expect that Lifevantage Corporation will post 0.6 earnings per share for the current fiscal year.
Lifevantage Increases Dividend
The firm also recently disclosed a quarterly dividend, which will be paid on Monday, June 15th. Shareholders of record on Monday, June 1st will be issued a dividend of $0.05 per share. This represents a $0.20 annualized dividend and a yield of 3.6%. This is a boost from Lifevantage’s previous quarterly dividend of $0.05. The ex-dividend date of this dividend is Monday, June 1st. Lifevantage’s payout ratio is currently 40.00%.
Insider Transactions at Lifevantage
In related news, Director Judd Dayton bought 10,500 shares of the business’s stock in a transaction on Monday, March 2nd. The stock was acquired at an average price of $4.53 per share, for a total transaction of $47,565.00. Following the purchase, the director directly owned 80,359 shares in the company, valued at $364,026.27. This trade represents a 15.03% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Over the last quarter, insiders have acquired 34,252 shares of company stock worth $157,940. Insiders own 21.95% of the company’s stock.
Hedge Funds Weigh In On Lifevantage
A number of institutional investors have recently bought and sold shares of the stock. DGS Capital Management LLC purchased a new position in shares of Lifevantage during the 1st quarter worth approximately $44,000. Hsbc Holdings PLC purchased a new position in Lifevantage in the 1st quarter worth approximately $51,000. JPMorgan Chase & Co. lifted its position in Lifevantage by 870.2% in the 2nd quarter. JPMorgan Chase & Co. now owns 5,016 shares of the company’s stock valued at $66,000 after acquiring an additional 4,499 shares in the last quarter. Franklin Resources Inc. purchased a new stake in shares of Lifevantage during the fourth quarter valued at $74,000. Finally, Aristides Capital LLC purchased a new stake in shares of Lifevantage during the fourth quarter valued at $76,000. 35.32% of the stock is owned by institutional investors.
About Lifevantage
LifeVantage Corporation is a publicly traded company that develops, markets and distributes nutritional supplements, skincare products and weight-management solutions through a direct-selling business model. The company’s flagship offering, Protandim®, is formulated to activate the Nrf2 pathway, which is associated with cellular defense processes. LifeVantage also markets the PhysIQ® line for metabolism and body composition support and the TrueScience® skincare regimen, targeting a range of health and wellness needs.
Founded in 1999 and headquartered in Sandy, Utah, LifeVantage combines research in nutrigenomics with a network of independent distributors to bring its products to market.